On April 4, 2024, 89Bio Entered Into Collaboration Agreement With BiBo Biopharma Engineering - Filing
On April 4, 2024, 89Bio Entered Into Collaboration Agreement With BiBo Biopharma Engineering - Filing
BiBo will construct a production facility specifically designed to supply the Company with pegozafermin for commercialization, if approved. Under the Collaboration Agreement, the Company will pay BiBo an aggregate of $135 million toward the construction of the Production Facility, of which 45% of the Payment will be payable in the third quarter of 2024. The remainder of the Payment will become payable upon achievement of certain specified milestones, of which up to an additional approximately 45% of the Payment could become payable within the next 12 months, depending on the timing of achievement of certain milestones.
如果获得批准，BiBo将建造一座专门为向公司提供pegozafermin用于商业化的生产设施。根据合作协议，公司将向BiBO支付总额为1.35亿美元的生产设施建设费用，其中45％的款项将在2024年第三季度支付。剩余的款项将在达到某些规定的里程碑后支付，其中最多可额外支付 45% 的款项将在未来12个月内支付，具体取决于某些里程碑的实现时间。